secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2023-10-06T23:59:59+00:00
Accession:  0000950170-23-052420
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics presents SEQUOIA-HCM baseline data: 282 patients enrolled, results due by end 2023
--------------------------------------------------------------------------------

- SEQUOIA-HCM enrolled 282 patients with symptomatic obstructive HCM; one third from US, half from Europe/Israel, remainder from China.
- Mean age 59.1 years, 40.4% female, 78.7% white; baseline NYHA class II 75.9%, III 23.8%, IV 0.4%.
- Background therapy: beta-blockers 61%, calcium channel blockers 26.6%, disopyramide 12.8%.
- Key blinded baseline data include LVEF, LVOT gradients, and NT-proBNP; top-line results still expected by end of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000095017023052420/0000950170-23-052420-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000095017023052420/cytk-20231006.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-052420

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer